Please check your internet connection and try again.
# Ezivac Enema
## Overview
Ezivac enema is a proprietary brand name for a **Sodium Phosphate** (monobasic and dibasic sodium phosphate) osmotic laxative. It works by increasing fluid accumulation in the colon, stimulating evacuation.
## Primary Indications
* Relief of occasional constipation.
* Bowel preparation prior to proctoscopic or sigmoidoscopic examination or surgery.
## Adult Dosing
* **Constipation:** 118 mL (one ready-to-use unit) administered rectally once daily or as directed by a physician.
* **Bowel Prep:** Up to 118 mL administered once or twice, depending on clinical requirements. Do not exceed one unit in a 24-hour period unless directed by a physician due to the risk of electrolyte disturbances.
## Pediatric Dosing
* **Children 2–11 years:** 59 mL (pediatric size) administered rectally as a single dose.
* **Children < 2 years:** Use is generally contraindicated; safety and efficacy are not established.
* **Note:** Always verify specific weight-based institutional protocols for pediatric bowel preparation.
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. Contraindicated in patients with renal insufficiency due to the risk of hyperphosphatemia, hypocalcemia, and hypernatremia.
* **Elderly:** Use with caution; monitor for dehydration and electrolyte shifts.
## Contraindications
* Hypersensitivity to any component.
* Known or suspected bowel obstruction, megacolon, or perforated bowel.
* Severe renal impairment.
* Congestive heart failure or clinically significant dehydration.
* Active inflammatory bowel conditions (e.g., ulcerative colitis).
## Adverse Effects
* **Electrolyte Imbalance:** Hyperphosphatemia, hypocalcemia, hypokalemia, and hypernatremia.
* **Gastrointestinal:** Rectal pain, irritation, tenesmus, and excessive bowel activity.
* **Systemic:** Dehydration, dizziness, and potential for cardiac arrhythmias if severe electrolyte shifts occur.
## Key Drug Interactions
* **ACE Inhibitors / ARBs / NSAIDs:** May increase the risk of acute kidney injury or renal failure due to osmotic diuresis and electrolyte changes.
* **Diuretics:** Potential for additive fluid and electrolyte depletion.
* **Calcium Channel Blockers:** Potential for increased risk of hypocalcemia-related complications.
## Monitoring
* Monitor serum electrolytes (sodium, phosphate, calcium, potassium) in high-risk patients.
* Assess volume status and signs of dehydration.
* Observe for signs of rectal mucosal injury or bleeding.
## Clinical Pearls
* **Administration:** Patient should be in the left lateral position (Sims' position) to follow the anatomical curvature of the colon.
* **Hydration:** Advise patients to maintain adequate oral fluid intake before and after administration to minimize risk of dehydration.
* **Retention:** Advise the patient to retain the enema until a strong urge to defecate is felt (usually 2–5 minutes).
* **Warning:** Chronic use may lead to dependency and loss of normal bowel function.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines vary by institution and region. Always verify specific dosing, safety precautions, and prescribing information with current official product monographs or institutional pharmacy guidelines before administration.
